Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2101

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2101
---
    SUPPLEMENTAL CASH FLOW INFORMATION: 

    Cash and cash equivalents 
    $3,252,304  
    $884,099  
    $1,521,499 
  
    Restricted cash 
     74,756  
     79,756  
     79,756 
  
    Cash, restricted cash and cash equivalents 
    $3,327,060  
    $963,855  
    $1,601,255 

    NON-CASH FINANCING ACTIVITIES: 

    Issuance of common shares to Keystone Capital LLC for equity line of credit 
    $500,000  
     -  
    $- 
  
    Issuance of common shares to Arena Capital Partners for equity line of credit 
    $500,000  
    $-  
    $- 
  
    Conversion of Series A and Series B preferred stock to common stock 
    $9,037,773  
    $-  
    $- 
  
    Stock subscription receivables 
    $803,044  
    $-  
    $- 
  
    Increase in deferred offering costs and accounts payable 
    $112,232  
    $-  
    $- 
  
    Exercise of warrants for Series A Preferred Stock through extinguishment of accrued expenses 
    $568,400  
    $-  
    $- 
  
    Deemed dividend – common stock liability, 13,835 shares 
    $85,500  
    $-  
    $- 

See accompanying notes to the consolidated financial
statements

F-6

CERO THERAPEUTICS HOLDINGS,
INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – Organization
and Description of the Business

Nature of Operations – CERo Therapeutics
Holdings, Inc. (NASDAQ: CERO), F/K/A Phoenix Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021.
PBAX was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar
business combination with one or more businesses (a “business combination”).

Reverse Stock Split – On January
8, 2025, we effected a reverse stock split of our shares of common stock at a ratio of 1-for-100 (the “Reverse Stock Split